This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Munafò, M. R. Articles by Lerman, C. Search for Related Content PubMed PubMed Citation Articles by Munafò, M. R. Articles by Lerman, C.

Lack of Association of 5-HTTLPR Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial

¹ Department of Experimental Psychology, University of Bristol, Bristol, United Kingdom; ² Cancer Research UK GPRG, Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom; ³ Tobacco Use Research Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania; and ⁴ Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia

Requests for reprints: Marcus R. Munafò, Department of Experimental Psychology, University of Bristol, 8 Woodland Road, Bristol BS8 1TN, United Kingdom. Phone: 44-117-9546841; Fax: 44-117-9288588. E-mail: marcus.munafo{at}bristol.ac.uk

	Introduction

Top Introduction Materials and Methods Results Discussion References

 
Cigarette smoking is the leading preventable cause of death worldwide, accounting for at least 30% of all cancer deaths and over three quarters (87%) of lung cancer deaths in developed countries; however, despite progress made in the treatment of tobacco dependence, available Food and Drug Administration–approved treatments are effective for only a fraction of smokers. The wide individual variation in therapeutic response has prompted a growing interest in the study of the role of inherited factors in the efficacy of alternate pharmacotherapies (1). To date, two pharmacogenetic trials of NRT have been conducted. Based on the neurobiology of reward (2, 3), pharmacogenetic analyses have focused on genes in the dopamine pathway (4-6) and the opioid pathway (7).

Other promising candidate genes for studies of smoking cessation pharmacogenetics exist. A functional polymorphism in the promoter region of the serotonin transporter (5-HTT) gene has been identified (5-HTTLPR) and is known to be associated with altered serotonin activity, with the short (S) form of this polymorphism being associated with reduced transcriptional efficiency of the 5-HTT promoter compared with the long (L) form, thereby decreasing serotonin transporter expression and serotonin uptake (8), while a recent positron emission tomography study also showed an association of this polymorphism with 5-HT1A binding in healthy volunteers (9).

A recent meta-analysis of case-control genetic association studies of smoking behaviors (10) noted that the 5-HTT gene showed evidence of association with smoking cessation, in a comparison of current smokers with ex-smokers, with possession of one or more copies of the S allele associated with a reduced likelihood of cessation. It is possible that the S allele influences smoking cessation via increased anxiety-related withdrawal symptomatology, given evidence for an association of this polymorphism with anxiety-related traits (11). However, no study has yet investigated the association of 5-HTTLPR genotype with smoking cessation in an explicitly designed study of smoking cessation or investigated possible genotype x treatment interaction effects.

We predicted that possession of one or more copies of the S allele of the 5-HTTLPR polymorphism would be associated with reduced likelihood of successful cessation. We also explored the possibility that NRT delivered via nasal spray might be more effective than NRT delivered via transdermal patch in smokers with one or more copies of the S allele, given that ad lib nasal spray delivery might be better suited to the relief of acute anxiety-related withdrawal symptomatology.

	Materials and Methods

Top Introduction Materials and Methods Results Discussion References

 
Three hundred and ninety-seven smokers of European ancestry, recruited by advertisements in local media in Philadelphia and Washington DC from February 2000 to April 2003, participated in this study. The trial was an open-label randomized clinical trial of transdermal patch versus nasal spray nicotine replacement therapy for smoking cessation. The University of Pennsylvania and Georgetown University Institutional Review Boards approved all study procedures, and all participants provided written, informed consent. All participants provided samples of whole blood for subsequent genotyping and cotinine analysis. To assess smoking status, telephone interviews were conducted at the end of treatment and at 6-month follow-up. Participants who reported completed abstinence for the previous 7 days were required to complete an in-person visit for biochemical verification of abstinence. Participants were genotyped for the 5-HTTLPR using primers as described by Heils et al. (8). The study is described in detail elsewhere (7).

Sustained abstinence, at end of treatment and 6-month follow-up, was the primary outcome measure. Self-reported abstinence at end of treatment and 6-month follow-up was confirmed by exhaled carbon monoxide monitoring (<10 ppm). Participants lost to follow-up were assumed to have relapsed to smoking (12) and coded as such in outcome analyses (i.e., intent to treat analyses). Separate models of outcome at end of treatment and 6-month follow-up were generated within a logistic regression framework because pharmacotherapy was available only during the treatment phase. Age, sex, and nicotine dependence score were entered in the first step, treatment group (transdermal patch and nasal spray) in the second step, and 5-HTTLPR genotype (LL, SL, and SS) and a genotype x treatment group interaction term in the third step. For comparisons involving 5-HTTLPR genotype, LL was the reference group. An level of 0.05 was maintained throughout.

The sample was adequate to detect small effects (Cohen's d = 0.3) corresponding to an odds ratio of 1.9 for the main effect of genotype. Power calculations were done using Power and Sample Size Software (NCSS, Kaysville UT).

	Results

Top Introduction Materials and Methods Results Discussion References

 
Genotype data were missing on four participants so that the final sample for analysis consisted of 393 smokers (53% male). The mean age of participants was 46 years 7 months (SD, 11 years 5 months; range, 20-78 years). 5-HTTLPR genotype frequencies by treatment group and abstinence at both end of treatment and 6-month follow-up are presented in Table 1. Genotype frequencies did not deviate significantly from Hardy-Weinberg equilibrium (P = 0.11).

	Discussion

Top Introduction Materials and Methods Results Discussion References

Although a recent meta-analysis (10) suggested that 5-HTTLPR genotype may be associated with smoking cessation, it should be borne in mind that the data included in this meta-analysis were derived from case-control studies using retrospective assessment of smoking status. Whereas the present study did follow participants prospectively for smoking cessation, the lack of a placebo arm precludes determination of the effects of 5-HTTLPR on unaided smoking cessation, and the results of the recent meta-analysis may reflect spontaneous, unaided cessation.

Nonetheless, the lack of an association at the end of the treatment phase or at 6-month follow-up suggests that this polymorphism is unlikely to play a major role in smoking cessation or response to nicotine replacement therapy. Whereas the direction of the main effect observed at the end of treatment phase was broadly consistent with our a priori hypothesis, with lowest overall cessation in the SS group, this was reversed at 6-month follow-up. Moreover, the direction of the interaction effect was opposite to that predicted by our a priori hypothesis, with the greatest relative benefit of patch over nasal spray observed in the SS group.

It remains a possibility that the effect sizes that we observed will be shown to be statistically significant in a future large-scale pharmacogenetic trial. Although our data do not give any reason to believe that 5-HTTLPR genotype is associated with smoking cessation, if the small effect sizes observed in our data are real, a sample of n = 7,200 would be required to achieve 80% power to show statistical significance for both the main effect of genotype and the genotype x treatment interaction. It is also possible that 5-HTTLPR genotype may be associated with response to other pharmacologic treatments for smoking cessation, in particular those with an antidepressant action, including bupropion and nortriptyline, as well as selective serotonin reuptake inhibitors. Future human behavioral pharmacology studies that test genotype and medication effects on intermediate phenotype measures (also known as endophenotypes, which may be biological more proximal to genetic antecedents of interest) may also be informative.

	Acknowledgments

 
We thank Pharmacia (Helsingborg, Sweden) for nicotine nasal spray.

	Footnotes

 
Grant support: Transdisciplinary Tobacco Use Research Center grant P5084718 from the National Cancer Institute and the National Institute on Drug Abuse (C. Lerman), Cancer Research UK Programme (E.C. Johnstone), and Unio Internationale Contra Cancrum American Cancer Society International Fellowship for Beginning Investigators (M.R. Munafò).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/23/05; revised 11/18/05; accepted 12/22/05.

	References

Top Introduction Materials and Methods Results Discussion References

 

1. Munafo MR, Shields AE, Berrettini WH, Patterson F, Lerman C. Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 2005;6:211–23.[CrossRef][Medline]
2. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247–91.[CrossRef][Medline]
3. Boyadjieva NI, Sarkar DK. The secretory response of hypothalamic ß-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 1997;61:PL59–66.[Medline]
4. Johnstone EC, Yudkin PL, Hey K, et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004;14:83–90.[CrossRef][Medline]
5. Yudkin P, Munafo M, Hey K, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. Br Med J 2004;328:989–90.[Free Full Text]
6. Lerman C, Jepson C, Wileyto EP, et al. The role of functional genetic variation in the dopamine D2 Receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006;31:231–42.[Medline]
7. Lerman C, Wileyto EP, Patterson F, et al. The functional µ opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 2004;4:184–92.[CrossRef][Medline]
8. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621–4.[Medline]
9. David SP, Murthy NV, Rabiner EA, et al. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci 2005;25:2586–90.[Abstract/Free Full Text]
10. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004;6:583–97.[CrossRef][Medline]
11. Munafo MR, Clark TG, Moore LR, Payne E, Walton R, Flint J. Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry 2003;8:471–84.[CrossRef][Medline]
12. Society for Research on Nicotine and Tobacco. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002;4:149–59.
13. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens. Nicotine Tob Res 2004;6:899–912.

This article has been cited by other articles:

				M. R. Munafo, E. C. Johnstone, M. F. G. Murphy, and P. Aveyard Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial Nicotine Tob Res, April 1, 2009; 11(4): 404 - 407. [Abstract] [Full Text] [PDF]

				M. Quaak, C. P. van Schayck, A. M. Knaapen, and F. J. van Schooten Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur. Respir. J., March 1, 2009; 33(3): 468 - 480. [Abstract] [Full Text] [PDF]

				M. Gwinn, I. Guessous, and M. Khoury "Intention to Analyze" in Pharmacogenomics Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 740 - 740. [Full Text] [PDF]

				M. R. Munafo, E. C. Johnstone, M. F.G. Murphy, and P. Aveyard "Intention to Analyze" in Pharmacogenomics Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 740 - 741. [Full Text] [PDF]

				E. C. Johnstone, K. M. Elliot, S. P. David, M. F.G. Murphy, R. T. Walton, and M. R. Munafo Association of COMT Val108/158Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1065 - 1069. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Munafò, M. R. Articles by Lerman, C. Search for Related Content PubMed PubMed Citation Articles by Munafò, M. R. Articles by Lerman, C.